

Date: July 13, 2021

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 540737

Dear Sir / Ma'am,

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the first quarter ended June 30, 2021.

Kindly take the same on your record.

Thanking you,

For, SHREE GANESH REMEDIES LIMITED

Aditya Patel
Company Secretary & Compliance Officer

Encl: As Above

PRESS RELEASE

Shree Ganesh Remedies Limited (“SGRL”) delivers top line and PBT growth of 42 % and 60 % respectively for Q1 F.Y. 2021-22

Ankleshwar, Gujarat - July 13, 2021 Shree Ganesh Remedies Limited (“SGRL”), pioneer in manufacturing of Bulk Drug Intermediates announced the financial results for the Quarter ended on June 30, 2021.

Overview of Results for Q1 2021-22 v/s Q1 2020-21:

(Rs. In Lakhs)

Particulars	Q1 2021-22	Q1 2020-21
Total Revenue	1374.09	986.20
EBDITA	416.39	261.46
EBDITA (% of total revenue)	30.30%	26.51%
PBT	327.89	203.91
PBT (% of total revenue)	23.86%	20.68%
PAT (Before OCI)	233.82	164.96
PAT (% of total revenue)	17.02%	16.73%
Cash Profit	315.35	220.18
Cash Profit (% of total revenue)	22.95%	22.33%
Basic / Diluted EPS (In Rs.)	2.34	1.65

- a) Earlier this Month SGRL had successfully commenced the commercial production of newly developed certain type of Cyclo-Propyl derivative, which is currently being imported by most of manufacturers in India for synthesis of the drugs like Naltrexone and Buprenorphine. Both the drugs are used as medication primarily used to manage alcohol or opioid use disorder by reducing cravings and ease the pain.
- b) Unlike the first wave, the second wave of pandemic was severe and resulted into shortage of shipping containers and timely clearance at the ports. Besides all the constraints in operations & Logistics, SGRL had delivered a strong EBDITA of

30.30 %. However SGRL believed since mid June, above issues have started to get resolved and the production along with the Logistics are getting back on track.

- c) “Despite of the Development of the New Product at it’s laboratory at Ankleshwar and commissioning of the new plant earlier this quarter SGRL remains **Net Zero Debt Entity**”, said Mr. Chandulal Kothia, MD, SGRL.

To view the results, please click on the link given below:

<https://www.ganeshremedies.com/investor/Financials-Results.pdf>

Media Contact Details

Sureshbhai Dalsukhbhai Panchal

Chief Financial Officer

091- 7574976076

cfo@ganeshremedies.com